Department of Neurosurgery, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, People's Republic of China.
Pathol Res Pract. 2012 Aug 15;208(8):437-43. doi: 10.1016/j.prp.2012.03.004. Epub 2012 Jun 8.
Hepatoma-derived growth factor (HDGF) plays an important role in tumor progression. Highly expressed HDGF has been found to indicate poor prognosis in many cancers. However, no information is available regarding the prognostic value of nuclear or cytoplasmic HDGF staining level in breast cancer. In the present study, the nuclear or cytoplasmic HDGF staining level was investigated in 86 patients with primary breast cancer by immunohistochemistry; the relationship between nuclear or cytoplasmic HDGF staining level and clinicopathological parameters was examined by Two-tailed Mann-Whitney U-test or Krustal-Wallis. The prognostic value of nuclear or cytoplasmic HDGF staining level in disease-free survival and overall survival was analyzed by Kaplan-Meier methods and log-rank test. We found that the percentage of cases with strong nuclear HDGF staining level was significantly higher in the cases with high tumor grade, high stage, high proliferation index (Ki-67 index>20%), as well as in those with lymph node invasion and recurrence (p<0.05) compared to those without. No significant correlation was found between cytoplasmic HDGF expression and any clinicopathological variables. In addition, disease-free survival and overall survival were significantly lower in patients with high nuclear HDGF expression (level 2) than in those with low nuclear HDGF expression (level 0 and level 1). Further Cox multivariate analysis showed that high nuclear HDGF expression is an independent factor for indicating poor prognosis in breast cancer patients. No significant difference in disease-free survival rate and overall survival was found between different cytoplasmic HDGF staining levels. All these findings suggest that increased nuclear HDGF expression is involved in tumor progression and might be used as a new prognosticator for breast cancer.
肝癌衍生生长因子 (HDGF) 在肿瘤进展中发挥重要作用。在许多癌症中，高表达的 HDGF 预示着不良预后。然而，目前尚无关于乳腺癌中核或细胞质 HDGF 染色水平的预后价值的信息。本研究通过免疫组织化学法检测了 86 例原发性乳腺癌患者的核或细胞质 HDGF 染色水平；通过双尾 Mann-Whitney U 检验或 Kruskal-Wallis 检验研究核或细胞质 HDGF 染色水平与临床病理参数之间的关系。通过 Kaplan-Meier 方法和对数秩检验分析核或细胞质 HDGF 染色水平在无病生存和总生存中的预后价值。我们发现，在高肿瘤分级、高分期、高增殖指数（Ki-67 指数>20%）、淋巴结浸润和复发的病例中，强核 HDGF 染色水平的病例百分比明显高于无淋巴结浸润和复发的病例（p<0.05）。细胞质 HDGF 表达与任何临床病理变量之间均无显著相关性。此外，核 HDGF 高表达（水平 2）患者的无病生存率和总生存率明显低于核 HDGF 低表达（水平 0 和水平 1）患者。进一步的 Cox 多因素分析表明，核 HDGF 高表达是乳腺癌患者预后不良的独立因素。不同细胞质 HDGF 染色水平之间无病生存率和总生存率无显著差异。所有这些发现表明，核 HDGF 表达的增加与肿瘤进展有关，可能作为乳腺癌的新预后指标。
